Last week CDRH posted a list of the guidance documents it plans to issue in FY 2018. Prioritized by an A and B list, final guidance priorities include a UDI policy regarding compliance dates of Class I and unclassified devices, and appropriate use of voluntary consensus standards in premarket submissions for medical devices.
Draft guidance priorities include export certificates, the HDE and 510(k) third party review program, multifunctional device products, and least burdensome provisions.
Included on the B-list of final guidance topics is human factors list of high priority devices, and the draft guidance topics include premarket submissions for patient matched guides to orthopedic implants.
CDRH also lists several final guidance documents from 1978, 1988, 1998, 2008 that are subject to focused retrospective review by the agency.
The full list is available on the agency’s website.
Related Articles
-
Cybersecurity, remanufacturing of devices and chemical analysis for biocompatibility assessment of medical devices are among the topics FDA plans to address through draft and final guidances in 2023.
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
-
The Experiential Learning Program (ELP) provides CDRH review staff with an opportunity to visit sites and gain a better understanding of the products they review. The 2023 ELP Site Visit Proposal period is open now until September 6, 2022.
-
The new guidance is intended to establish confidence in automation used for production or quality assurance systems and describe various methods and testing activities that may be applied to establish computer software assurance and meet regulatory software validation requirements.
